Home › SEC Filings › Insider Cluster Activity
Insider Cluster Activity
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CRL | CLUSTER | neutral | 2/10 | 🔒Two CRL insiders sold a combined $9.16M in open-market sales, all under 10b5-1 trading plans. Director Foster's $8.41M s | Oct 26, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt sold ~$5.5M in open-market shares on October 22, 2026, following an option exercise, while EVP & G | Oct 23, 2026 |
| RAPP | CLUSTER | bullish | 5/10 | A cluster of insider purchases at Rapport Therapeutics, Inc. (RAPP) shows five directors and the CFO buying a total of ~ | Oct 23, 2026 |
| PVLA | CLUSTER | neutral | 2/10 | Two Palvella insiders — COO Kathleen Goin and Director George Jenkins — sold a combined $310K in open-market shares over | Oct 23, 2026 |
| RAPP | CLUSTER | bullish | 5/10 | Two insiders at Rapport Therapeutics, including the CFO and a director, made open-market purchases totaling $361K over t | Oct 21, 2026 |
| UTHR | CLUSTER | bearish | 4/10 | CEO Martine Rothblatt exercised options and sold a large block of shares on October 20, 2026, while EVP & General Counse | Oct 21, 2026 |
| ELVN | CLUSTER | neutral | 3/10 | Two senior executives at Enliven Therapeutics (CMO and CFO) sold a combined $424K in open-market sales on October 19, 20 | Oct 21, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt sold a large block of shares on October 19, 2026, exercising options and immediately selling the r | Oct 21, 2026 |
| CSTL | CLUSTER | neutral | 3/10 | Two Castle Biosciences insiders, including the CEO, sold a combined $384K in open-market sales over a one-week window. T | Oct 21, 2026 |
| ORKA | CLUSTER | neutral | 3/10 | Two insiders at Oruka Therapeutics sold a total of $534K in open-market sales within a week. The CMO exercised and sold | Oct 20, 2026 |
| CRSP | CLUSTER | bearish | 5/10 | Three insiders at CRISPR Therapeutics sold a total of ~$3.15M in open-market sales within a week, including the CEO ($2. | Oct 20, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined ~$479K in open-market sales over a 7-day window, with Rothblatt | Oct 20, 2026 |
| CTY | CLUSTER | bullish | 6/10 | Two 10% owners, including director Robert Nelsen and ARCH Venture Partners XII, LLC, each purchased 170,000 shares of Ci | Oct 19, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined $558K in open-market shares on October 15-16, 2026. The sales f | Oct 18, 2026 |
| ANIP | CLUSTER | bearish | 4/10 | Two ANIP insiders, including the CEO, sold a total of $425K in open-market sales over a week. The CEO's $388K sale is th | Oct 16, 2026 |
| CRSP | CLUSTER | neutral | 3/10 | Three CRSP insiders, including the CEO and a director, sold a combined ~$973K in open-market sales over a two-day window | Oct 16, 2026 |
| CRSP | CLUSTER | bearish | 4/10 | Three CRISPR Therapeutics insiders, including the CEO and General Counsel, sold a total of ~$973K in open-market sales o | Oct 16, 2026 |
| PTCT | CLUSTER | neutral | 3/10 | Two PTCT insiders — a director and the EVP & CLO — sold a combined $138K in shares over a one-week window. The sales are | Oct 16, 2026 |
| MPLT | CLUSTER | bearish | 4/10 | CEO Christopher Kroeger and CAO/Interim CFO Jonathan Gillis sold a combined $678K in open-market sales on October 15, 20 | Oct 16, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined $1.38M in open-market sales, with the CEO exercising and immedi | Oct 16, 2026 |
| GILD | CLUSTER | neutral | 2/10 | Two GILD C-suite executives (CFO and Chief Communications & Corporate Affairs Officer) each sold $469K worth of stock on | Oct 16, 2026 |
| ORKA | CLUSTER | neutral | 3/10 | Two insiders at Oruka Therapeutics sold a total of ~$380K in open-market sales over a one-week window. The CMO sold $211 | Oct 15, 2026 |
| CRSP | CLUSTER | neutral | 3/10 | CEO Samarth Kulkarni and General Counsel James Kasinger sold a combined $253K in CRSP stock on October 14, 2026, at $49. | Oct 15, 2026 |
| NRIX | CLUSTER | neutral | 3/10 | Nurix Therapeutics director Julia P. Gregory executed a same-day derivative exercise and open-market sale of 22,583 shar | Oct 15, 2026 |
| CUE | CLUSTER | bearish | 4/10 | CEO Lin Shao-Lee and VP Meluzio Michael Vincent sold a combined $307K in open-market sales on October 12, 2026. The CEO' | Oct 14, 2026 |
| ONMD | CLUSTER | bullish | 6/10 | Two insiders at OneMedNet Corp, including a director/10% owner and the Chief Medical Officer, made open-market purchases | Oct 13, 2026 |
| LQDA | CLUSTER | neutral | 4/10 | Two Liquidia Corp insiders (Chief Business Officer and Chief Accounting Officer) sold a combined $376K in open-market sa | Oct 13, 2026 |
| RTSN | CLUSTER | bullish | 5/10 | Two insiders at Retension Pharmaceuticals, including CEO Eric Keller and Director Franklin Berger, made open-market purc | Oct 13, 2026 |
| TWST | CLUSTER | bearish | 6/10 | Six Twist Bioscience insiders, including the CEO, President/COO, and CFO, sold a combined $17.86M in shares over a one-w | Oct 12, 2026 |
| ADPT | CLUSTER | neutral | 3/10 | Two senior executives at Adaptive Biotechnologies (Chief People Officer and President/COO) sold a combined ~$390K in ope | Oct 5, 2026 |
Page 1 of 42 Next »